Fitchburg’s Promega Corp. and Aobious Inc., based in Gloucester, Massachusetts, have entered into a settlement agreement to resolve a patent infringement lawsuit related to furimazine and its associated variants.
Furimazine is a substrate (underlying substance) for NanoLuc luciferase, an enzyme introduced by Promega in 2012. When NanoLuc luciferase interacts with its substrate, it produces an exceptionally bright luminescent signal. Promega assay platforms such as NanoBiT and Lumit technologies enable researchers to use that signal to study proteins in live cells.
On July 15, the U.S. District Court for the District of Delaware entered a final consent judgment confirming that Aobious infringed four Promega patents, issuing a permanent injunction against Aobious and requiring Aobious to make monetary payments to Promega as agreed upon in the settlement terms.
